| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |